MAINZ — BioNTech SE (Nasdaq: BNTX) has finalized its acquisition of InstaDeep Ltd. (“InstaDeep”), a renowned global AI and machine learning technology company. The acquisition, initially announced on January 10, 2023, solidifies BioNTech’s commitment to advancing AI-driven drug discovery and developing cutting-edge immunotherapies and vaccines to tackle diseases with significant unmet medical needs. This move follows BioNTech’s earlier equity investment in InstaDeep during its Series B financing round in January 2022, marking a continued collaboration between the two entities since 2019, according to a press release published on EuropaWire .
The acquisition aligns with BioNTech’s strategic vision, enhancing its position as a leader in AI-driven biomedical research. As part of the deal, InstaDeep will function as a UK-based subsidiary of BioNTech, maintaining its global operations and clientele across various sectors, including Technology, Transport & Logistics, Industrial, and Financial Services. The acquisition brings approximately 290 skilled professionals in AI, ML, bioengineering, data science, and software development to BioNTech’s workforce.
The total consideration for the acquisition, excluding BioNTech’s previously owned shares in InstaDeep, stands at approximately €500 million. This includes a combination of cash, BioNTech shares, and performance-based future milestone payments, underlining BioNTech’s commitment to leveraging AI for innovative medical solutions.